Clinical trials update from the American College of Cardiology meeting: CARE-HF and the Remission of Heart Failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER

European Journal of Heart Failure

Volumn 7, Issue 5, 2005, Pages 931-936

  Cleland, John G F ^a   Coletta, Alison P ^a   Freemantle, Nick ^b   Velavan, Periaswamy ^a   Tin, Lwin ^a   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CANPAP; CARE HF and the Remission of Heart Failure; COMPASS HF; PEECH; PREMIER; TNT; VERITAS; Women's Health Study

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE INHIBITOR; PG 116800; TEZOSENTAN; UNCLASSIFIED DRUG;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CENTRAL SLEEP APNEA SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DEVICE; HEALTH STATUS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MORTALITY; OXYGEN CONSUMPTION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REMISSION; SEX ROLE; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

CARDIAC PACING, ARTIFICIAL; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXAMIC ACIDS; REMISSION INDUCTION;

EID: 23744479851     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.04.002     Document Type: Conference Paper

References (20)

1. A.P. Coletta, J.G.F. Cleland, N. Freemantle, and A.L. Clark Clinical trials update from the European Society of Cardiology heart failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy Eur J Heart Fail 6 2004 673 676
2. J.G.F. Cleland, L.J. Kappenberger, L. Tavazzi, W. Klein, and E. Erdmann Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony Eur J Heart Fail 3 2001 481 489
3. J.G.F. Cleland on behalf of the CARE-HF study Steering Committee and Investigators Baseline characteristics of patients recruited into the CARE-HF study Eur J Heart Fail 7 2005 205 214
4. J.G.F. Cleland for the CARE-HF study Investigators The effect of cardiac resynchronisation on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
5. M.R. Bristow for the COMPANION investigators Cardiac resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med 350 2004 2140 2150
6. E. Lonn for the HOPE and HOPE-TOO trial investigators Effects of long term vitamin E supplementation on cardiovascular events and cancer: a randomised controlled trial JAMA 293 2005 1338 1347
7. B.G. Brown, and J. Crowley Is there any hope for vitamin E? JAMA 293 2005 1387 1390
8. Wood S. Vitamin E increases all-cause mortality. www.theheart.org November 10 2004.
9. P.M. Ridker, N.R. Cook, I.M. Lee, D. Gordon, J.M. Gaziano, and J.E. Manson A randomised trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
10. J.G. Cleland Is aspirin the "weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease Prog Cardiovasc Dis 44 2002 275 292
11. C.P. Cannon for the PROVE-IT TIMI 22 study Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
12. J.C. LaRosa for the TNT investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
13. M. Rauchhaus, A.L. Clark, W. Doehner, C. Davos, A. Bolger, and R. Sharma The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 42 2003 1933 1944
14. T.B. Horwich, W.R. MacLellan, and G.C. Fonarow Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure J Am Coll Cardiol 43 2004 642 648
15. D. Mozaffarian, R. Nye, and W.C. Levy Statin therapy is associated with lower mortality among patients with severe heart failure Am J Cardiol 93 2004 1124 1129
16. L. Tavazzi, G. Tognoni, M.G. Franzosi, R. Latini, A.P. Maggioni, and R. Marchioli Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure Eur J Heart Fail 6 2004 635 641
17. M. Packer on behalf of the ATLAS study group Comparative effects of low and high doses of the angiotensin converting enzyme inhibitor lisinopril on morbidity and mortality in chronic heart failure Circulation 100 1999 2312 2318
18. G. Cotter, E. Kaluski, K. Stangl, R. Pacher, and C. Richter The hemodynamic and neurohormonal effects of low dose tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure Eur J Heart Fail 6 2004 601 609
19. T.D. Bradley for the CANPAP investigators Rationale and design of the Canadian Positive Airway Pressure Trial for congestive heart failure patients with central sleep apnoea: CANPAP Can J Cardiol 17 2001 677 684
20. A.M. Feldman, M.A. Silver, G.S. Francis, P.A. De Lame, and W.W. Parmley Treating heart failure with enhanced external counterpulsation (EECP): design of the prospective evaluation of EECP in heart failure (PEECH) trial J Card Fail 11 2005 240 245